NCT01015911

A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma

A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: Seagen Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Conditions

• Carcinoma, Renal Cell
• Lymphoma, Non-Hodgkin

Interventions

Type	Name	Description
DRUG	SGN-75	SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg

Timeline

• Start date: 2009-11-01
• Primary completion: 2011-11-01
• Completion: 2012-03-01
• First posted: 2009-11-18
• Last updated: 2014-12-18

Locations

9 sites across 1 country: United States